• Stanford BMT-CT Presentations at 2021 ASTCT Meetings
  
• 79 Anti-CD22 CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Matthew J. Frank, MD, PhD¹, John Baird, MD¹, Juliana Craig¹, Shabnum Patel², Jay Spiegel, MD¹, Bita Sahaf, PhD³, Sheren F. Younes, MD, PhD⁴, Jean S. Oak, MD, PhD⁴, Yasodha Natkunam, MD, PhD⁴, Zachary Ehlinger, MS², Warren D. Reynolds, BS², Sally Arai, MD¹, Laura Johnston, MD¹, Robert Lowsky, MD¹, Robert S. Negrin, MD⁵, Andrew R. Rezvani, MD¹, Parveen Shiraz, MD¹, Surbhi Sidana, MD¹, Wen-Kai Weng, MD, PhD¹, Liora Schultz, MD⁶, Sneha Ramakrishna, MD⁷, Kara L Davis, DO⁸, Steven Feldman, PhD², Crystal L Mackall, MD⁹, David B. Miklos, MD, PhD¹ and Lori Muffly, MD, MS¹, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (3)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (4)Department of Pathology, Stanford University, Stanford, CA, (5)Stanford University School of Medicine, Stanford, CA, (6)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (7)Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, (8)Division of Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, (9)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanfod, CA
• 153 Concordance of Next Generation Sequencing-Based Measurable Residual Disease between Peripheral Blood and Bone Marrow in Adults with Acute Lymphoblastic Leukemia Receiving Cellular Therapies Lori Muffly, MD, MS¹, Vandana Sundaram², Sally Arai, MD¹, Matthew J. Frank, MD, PhD¹, Laura Johnston, MD¹, Robert Lowsky, MD¹, Everett H. Meyer, MD, PhD¹, Robert S. Negrin, MD³, Andrew R. Rezvani, MD¹, Surbhi Sidana, MD¹, Parveen Shiraz, MD⁴, Judith A. Shizuru, MD, PhD¹, Wen-Kai Weng, MD, PhD¹ and David B. Miklos, MD, PhD³, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Stanford University, Palo Alto, CA, (3)Stanford University School of Medicine, Stanford, CA, (4)Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA
• 154 Impact of Conditioning Regimen and Donor Type on Outcomes of Allogeneic Stem Cell Transplant for Myelofibrosis – a Single Institutional Experience Parveen Shiraz, MD¹, Surbhi Sidana, MD¹, Wen-Kai Weng, MD, PhD¹, Waqas Jehangir, MD², Robert S. Negrin, MD³, David B. Miklos, MD, PhD¹, Robert Lowsky, MD¹, Andrew R. Rezvani, MD¹, Judith A. Shizuru, MD, PhD¹, Matthew J. Frank, MD, PhD¹, Everett H. Meyer, MD, PhD¹, Laura Johnston, MD¹, Lori Muffly, MD, MS¹ and Sally Arai, MD¹, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Stanford University, Stanford, CA, (3)Stanford University School of Medicine, Stanford, CA
• 231 Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity Andrew Johnsrud, MD¹, Juliana Craig¹, John Baird, MD¹, Jay Spiegel, MD¹, Lori Muffly, MD, MS¹, James L. Zehnder, MD², Robert S. Negrin, MD³, Laura Johnston, MD¹, Sally Arai, MD¹, Judith A. Shizuru, MD, PhD¹, Robert Lowsky, MD¹, Everett H. Meyer, MD, PhD¹, Wen-Kai Weng, MD, PhD¹, Parveen Shiraz, MD¹, Andrew R. Rezvani, MD¹, Theresa M. Latchford, RN, MS, CNS, BMTCN, AOCNS¹, Crystal L Mackall, MD⁴, David B. Miklos, MD, PhD¹, Matthew J. Frank, MD, PhD¹ and Surbhi Sidana, MD¹, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Deptartment of Pathology, Stanford University School of Medicine, Stanford, CA, (3)Stanford University School of Medicine, Stanford, CA, (4)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanfod, CA
• 481 Utilization of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Emily C. Liang, MD¹, Lori Muffly, MD, MS², Parveen Shiraz, MD², Judith A. Shizuru, MD, PhD², Laura Johnston, MD², Sally Arai, MD², Wen-Kai Weng, MD, PhD², Robert Lowsky, MD², Andrew R. Rezvani, MD², Everett H. Meyer, MD, PhD³, Matthew J. Frank, MD, PhD², Robert S. Negrin, MD², David B. Miklos, MD, PhD² and Surbhi Sidana, MD², (1)Department of Medicine, Stanford University School of Medicine, Stanford, CA, (2)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (3)Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA
• 501 Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide Mobilization Vs. G-CSF +/- Plerixafor Mobilization in the Lenalidomide Era Andrew Johnsrud, MD¹, Abdullah Ladha, MD¹, Lori Muffly, MD, MS¹, Parveen Shiraz, MD¹, Judith A. Shizuru, MD, PhD¹, Laura Johnston, MD¹, Sally Arai, MD¹, Wen-Kai Weng, MD, PhD¹, Robert Lowsky, MD¹, Andrew R. Rezvani, MD¹, Everett H. Meyer, MD, PhD¹, Matthew J. Frank, MD, PhD¹, Robert S. Negrin, MD², David B. Miklos, MD, PhD¹ and Surbhi Sidana, MD¹, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Stanford University School of Medicine, Stanford, CA
• LBA6 Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation: A Single Center Report Andriyana K. Bankova, MD¹, Joseph Caveney, MD¹, Teresa L. Ramos, PhD¹, Jan L. Bögeholz, MD², Kartoosh Heydari, MD¹, Nery Diaz¹, Marin L. Jackson¹, Robert Lowsky, MD¹, Janice (Wes) Brown, M.D.¹, Laura Johnston, MD¹, Andrew R. Rezvani, MD¹, Matthew J. Frank, MD, PhD¹, Lori Muffly, MD, MS¹, Wen-Kai Weng, MD, PhD¹, Surbhi Sidana, MD¹, Robert S. Negrin, MD¹, David B. Miklos, MD, PhD¹, Parveen Shiraz, MD¹, Everett H. Meyer, MD, PhD¹, Judith A. Shizuru, MD, PhD¹ and Sally Arai, MD¹, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Divisions of Hematology & Oncology, Stanford University, Stanford, CA
•  88 Orca-T, a Precision T_reg-Engineered Donor Product, in Myeloablative HLA-Matched Transplantation Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience Everett H. Meyer, MD, PhD¹, Rasmus Hoeg², Anna Moroz, MD, PhD³, Bryan J. Xie, B.S.⁴, Hsin-Hsu Wu³, Rahul Pawar³, Kartoosh Heydari³, David B. Miklos, MD, PhD¹, Parveen Shiraz, MD¹, Lori Muffly, MD, MS¹, Sally Arai, MD¹, Laura Johnston, MD¹, Robert Lowsky, MD¹, Andrew R. Rezvani, MD¹, Judith A. Shizuru, MD, PhD¹, Wen-Kai Weng, MD, PhD¹, Nathaniel Fernhoff, PhD⁵, Gerhard Bauer⁶, Arpita Ghandi⁷, James Scott McClellan, MD, PhD⁵, Bronwen E. Shaw, MD, PhD⁸, Caspian Oliai, MD⁹, Joseph P. McGuirk, DO¹⁰, Mehrdad Abedi, MD¹¹ and Robert S. Negrin, MD¹², (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Hematology/Oncology, University of California, Davis, Sacramento, CA, (3)Stanford University, Stanford, CA, (4)Division of Blood and Marrow Transplantation, Department of Medicine, Stanford Medicine, Stanford, CA, (5)Orca Bio, Menlo Park, CA, (6)University of California, Davis, Davis, CA, (7)Oregon Health Sciences University, Portland, OR, (8)CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, CIBMTR and the Medical College of Wisconsin, Milwaukee, WI, (9)University of California, Los Angeles, Los Angeles, CA, (10)The University of Kansas Cancer Center, Westwood, KS, (11)Hematology/Oncology, University of California Davis Medical Center, Sacramento, CA, (12)Stanford University School of Medicine, Stanford, CA
• 92 HLA Class I Genotypes with Predicted Strong Binding Affinity to Mutated NPM1 Are Associated with Lower Relapse Risk in Matched Related or Unrelated Transplant for NPM1 Mutated Acute Myeloid Leukemia Rupa Narayan, MD, Massachusetts General Hospital, Boston, MA, Abhishek Niroula, Broad Institute, Cambridge, MA, Tao Wang, PhD, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, Michelle Kuxhausen, MS, Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, Everett H. Meyer, MD, PhD, Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, Yi-Bin Chen, MD, Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, Steven GE Marsh, BSc, ARCS, PhD, Anthony Nolan Research Institute, London, United Kingdom, Shahinaz M Gadalla, MD, PhD, Clinical Genetics Branch, National Cancer Institute, Rockville, MD, Sophie Paczesny, MD, PhD, Medical University of South Carolina, Charleston, SC, Stephen R. Spellman, MBS, NMDP/CIBMTR, Minneapolis, MN and Stephanie J Lee, MD, MPH, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
• 160 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia Vanessa E Kennedy, MD¹, Gavin Hui, MD², Daria Gaut, MD³, Varun Mittal, MD⁴, Caspian Oliai, MD³, Lori Muffly, MD, MS⁵, Aaron C. Logan, MD, PhD⁴ and Gabriel N. Mannis, MD⁶, (1)Division of Hematology/Oncology, Department of Medicine, UCSF, San Francisco, CA, (2)Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA, (3)University of California, Los Angeles, Los Angeles, CA, (4)University of California, San Francisco, San Francisco, CA, (5)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (6)Stanford University, Stanford, CA
• LBA5 Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, with Low Dose Irradiation and Fludarabine in Older Adults with MRD-Positive AML/MDS Undergoing Allogeneic HCT Lori Muffly, MD, MS¹, Hye-Sook Kwon, PhD², Michelle Chin, BS¹, Cara Lieber², Steve Smith³, Judith A. Shizuru, MD, PhD¹, Wendy W. Pang, MD, PhD² and Andrew S. Artz, MD⁴, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Jasper Therapeutics, Inc., Redwood City, CA, (3)Independent, San Jose, CA, (4)Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA
• 18 Anti-CD117 Antibody Synergizes with 5-Azacytidine to Augment Engraftment of Hematopoietic Stem Cells in Mice with Sickle Cell Disease Andriyana K. Bankova, MD¹, Wendy W. Pang, MD, PhD¹, Brenda J. Velasco¹, Jessica Poyser¹, Janel Long-Boyle, PharmD, PhD^2,3 and Judith A. Shizuru, MD, PhD^1,4,5, (1)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA, (3)Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, (4)Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford, CA, (5)Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA
• 249 Non-Toxic Single Agent Transplant Conditioning with JSP191 (an Anti-CD117 monoclonal antibody) in Infants with Newly Diagnosed Severe Combined Immune Deficiency Rajni Agarwal, MD¹, Christopher C Dvorak, MD², Theodore B Moore, MD³, Hye-Sook Kwon, PhD⁴, Janel Long-Boyle, PharmD, PhD^2,5, Anne Le⁶, Kenny Truong, RN, BSN², Donald B. Kohn, MD⁷, Kathryn Bradford, MD³, Satiro N De Olivera³, Alice Bertaina, MD, PhD⁸, Agnieszka Czechowicz, MD, PhD⁹, Matthew Porteus, MD, PhD^9,10, Ami J. Shah, MD⁹, David C. Shyr, MD⁸, Katja G. Weinacht, MD, PhD⁹, Melissa Mavers, MD, PhD⁹, Elisabeth Merkel, RN⁹, Andres Vargas, MD³, Nicole Harada¹¹, Janice (Wes) Brown, M.D.⁶, Wendy W Pang, MD, PhD¹¹, Robertson Parkman, MD⁹, Kenneth I Weinberg, MD⁹, Maria Grazia Roncarolo, MD^6,9,10 and Judith A. Shizuru, MD, PhD^6,9,10, (1)Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, (2)Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA, (3)Department of Pediatric Hematology-Oncology, University of California, Los Angeles, Los Angeles, CA, (4)Jasper Therapeutics, Inc., Redwood City, CA, (5)Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, (6)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (7)Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, (8)Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, (9)Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA, (10)Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, (11)Jasper Therapeutics, Redwood City, CA

93 Lower Respiratory Tract Infections and Lung Function in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplant Emily C. Liang, MD¹, David J. Epstein, MD², Joanna Nelson, MD², Husham Sharifi, MD³, Yu Kuang Lai, MD³, Sally Arai, MD⁴ and Joe L. Hsu, MD, MPH³, (1)Department of Medicine, Stanford University School of Medicine, Stanford, CA, (2)Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, (3)Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, (4)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA